FDA Clears Path for AXPAXLI: Ocular Therapeutix Targets Late 2026 NDA Submission

Ocular Therapeutix has reached alignment with the FDA to submit the AXPAXLI NDA for wet AMD in Q4 2026, based on SOL-1 data and interim SOL-R safety results. Topline SOL-R data now expected in Q1 2028.